A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy

Rades, Dirk; Dziggel, Liesa; Blanck, Oliver; Gebauer, Niklas; Bartscht, Tobias; Schild, Steven E.

doi:10.21873/anticanres.12570

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in order to establish a risk score predictor of brain recurrence after GSK, Rades et al analyzed the clinico-radiological characteristics of 45 BMRCC patients who underwent GSK, and identified two groups of patients with significantly different risk of recurrence. In particular, patients with multiple brain metastasis (>3), with an infratentorial location, were considered at high risk of recurrence outside the irradiated area [ 43 ].…”

Section: Current Treatment Strategiesmentioning

confidence: 99%

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview

Internò

Santis

Stucci

et al. 2021

Cancers

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of primary cancers that frequently metastasize to the brain. Brain metastasis derived from RCC has the propensity of intratumoral hemorrhage and relatively massive surrounding edema. Moreover, it confers a grim prognosis in a great percentage of cases with a median overall survical (mOS) around 10 months. The well-recognized prognostic factors for brain metastatic renal cell carcinoma (BMRCC) are Karnofsky Performance Status (KPS), the number of brain metastasis (BM), the presence of a sarcomatoid component and the presence of extracranial metastasis. Therapeutic strategies are multimodal and include surgical resection, radiotherapy, such as stereotactic radiosurgery due to the radioresistance of RCC and systemic strategies with tyrosin kinase inhibitors (TKI) or Immune checkpoint inhibitors (ICI) whose efficacy is not well-established in this setting of patients due to their exclusion from most clinical trials. To date, in case of positive prognostic factors and after performing local radical therapies, such as complete resection of BM or stereotactic radiosurgery (SRS), the outcome of these patients significantly improves, up to 33 months in some patients. As a consequence, tailored clinical trials designed for BMRCC are needed to define the correct treatment strategy even in this poor prognostic subgroup of patients.

show abstract

Section: Current Treatment Strategiesmentioning

confidence: 99%

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview

Internò

Santis

Stucci

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Patients with renal cell carcinoma (RCC) account for about 5% of patients with intracerebral metastases (1,2). Since RCC is considered a less radiosensitive tumor, patients with a limited number of intracerebral lesions are preferably treated with local therapies including radiosurgery and fractionated stereotactic radiotherapy alone or combined with whole-brain irradiation (WBRT) (3)(4)(5)(6)(7)(8). Patients with multiple lesions and those with significant co-morbidities and a markedly reduced performance status are often assigned to WBRT alone (1).…”

mentioning

confidence: 99%

Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool

2019

View full text Add to dashboard Cite

Background/Aim: A new tool for estimating survival of patients receiving whole-brain radiotherapy (WBRT) for intracerebral metastases from renal cell carcinoma (RCC) was created. Patients and Methods: The new WBRT-30-RCC was developed in 34 patients homogeneously treated with 30 Gy in 10 fractions of WBRT and compared to updated diagnosis-specific graded prognostic assessment DS-GPA and Dziggel score for predicting death within 6 months and survival for at least 6 months following WBRT. Results: WBRT-30-RCC included three groups with 6-month survival rates of 6.7% for those with 8-10 points, 38.5% for those with 12-14 points and 66.7% for those with 16-18 points. Positive predictive values (PPV)s for predicting death within 6 months were 93.3% using WBRT-30-RCC, 77.3% using updated DS-GPA and 93.7% using the Dziggel score. PPVs for predicting survival for at least 6 months were 66.7%, 50.0% and 50.0%, respectively. Conclusion: WBRT-30-RCC was more precise than the other scores in predicting survival for at least 6 months, although all three scores were not optimal. For predicting death within 6 months, WBRT-30-RCC and Dziggel score were similarly accurate and superior to the updated DS-GPA.

show abstract

A meta-analysis of stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer

Liu¹,

Lei²

2019

WCJD

View full text Add to dashboard Cite

A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy

Abstract: This study identified three risk groups regarding new brain metastases after stereotactic irradiation. Patients with 2 points could benefit from additional whole-brain radiotherapy.

Cited by 4 publications

References 10 publications

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview

Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool

A meta-analysis of stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer

Contact Info

Product

Resources

About